Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM) Meeting Abstract
| Authors: | Strowd, R. E.; Ellingson, B. M.; Wen, P. Y.; Ahluwalia, M. S.; Piotrowski, A. F.; Desai, A. S.; Clarke, J. L.; Lieberman, F. S.; Desideri, S.; Nabors, L. B.; Ye, X.; Grossman, S. A. |
| Abstract Title: | Safety and activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrent glioblastoma (GBM) |
| Meeting Title: | 55th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 37 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2019 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2019-05-20 |
| Start Page: | 93s |
| Language: | English |
| ACCESSION: | WOS:000487345804409 |
| DOI: | 10.1200/JCO.2019.37.15_suppl.2027 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2027 -- Source: Wos |
